What is William Blair's Estimate for IONS Q1 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at William Blair upped their Q1 2025 EPS estimates for Ionis Pharmaceuticals in a research note issued on Monday, April 14th. William Blair analyst M. Minter now anticipates that the company will earn ($1.23) per share for the quarter, up from their prior forecast of ($1.25). William Blair has a "Outperform" rating on the stock. The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.50) per share. William Blair also issued estimates for Ionis Pharmaceuticals' Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($3.84) EPS and FY2026 earnings at ($2.11) EPS.

Several other research analysts have also commented on IONS. Guggenheim reaffirmed a "buy" rating on shares of Ionis Pharmaceuticals in a research report on Thursday, April 3rd. StockNews.com raised shares of Ionis Pharmaceuticals to a "sell" rating in a research report on Tuesday, March 18th. BMO Capital Markets reduced their target price on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a report on Thursday, February 20th. HC Wainwright assumed coverage on Ionis Pharmaceuticals in a research report on Monday, April 7th. They issued a "buy" rating and a $45.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price objective on Ionis Pharmaceuticals from $47.00 to $45.00 and set a "neutral" rating for the company in a research report on Monday, March 24th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.72.

Ionis Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ IONS traded up $0.05 during midday trading on Thursday, hitting $28.40. 842,691 shares of the company's stock were exchanged, compared to its average volume of 1,522,365. The firm's fifty day simple moving average is $30.86 and its 200-day simple moving average is $34.20. The company has a debt-to-equity ratio of 2.12, a current ratio of 8.47 and a quick ratio of 8.82. The company has a market cap of $4.51 billion, a PE ratio of -9.34 and a beta of 0.29. Ionis Pharmaceuticals has a twelve month low of $23.95 and a twelve month high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. During the same quarter in the previous year, the company earned $0.12 earnings per share. The firm's quarterly revenue was down 30.2% compared to the same quarter last year.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 13,242 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $32.45, for a total transaction of $429,702.90. Following the completion of the transaction, the chief executive officer now directly owns 219,526 shares in the company, valued at $7,123,618.70. This represents a 5.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Eric Swayze sold 1,367 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $32.31, for a total transaction of $44,167.77. Following the transaction, the executive vice president now directly owns 48,017 shares of the company's stock, valued at $1,551,429.27. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,167 shares of company stock valued at $2,010,458 in the last ninety days. Company insiders own 2.71% of the company's stock.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of Ionis Pharmaceuticals by 9.4% during the fourth quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company's stock worth $575,880,000 after purchasing an additional 1,416,781 shares in the last quarter. Capital World Investors lifted its holdings in Ionis Pharmaceuticals by 46.5% during the 4th quarter. Capital World Investors now owns 11,465,413 shares of the company's stock worth $400,831,000 after buying an additional 3,637,041 shares in the last quarter. Orbimed Advisors LLC boosted its position in Ionis Pharmaceuticals by 21.2% in the 4th quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company's stock valued at $98,494,000 after buying an additional 492,900 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Ionis Pharmaceuticals by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 2,687,248 shares of the company's stock valued at $93,976,000 after buying an additional 18,890 shares during the period. Finally, Norges Bank bought a new stake in shares of Ionis Pharmaceuticals during the fourth quarter worth $59,948,000. Institutional investors own 93.86% of the company's stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.